Pulmonary Fibrosis - Pipeline Review, H2 2013:Industry Analysis Report


Published on

Pulmonary Fibrosis - Pipeline Review, H2 2013:Industry Analysis Report @ http://www.researchmoz.us/pulmonary-fibrosis-pipeline-review-h2-2013-report.html

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Pulmonary Fibrosis - Pipeline Review, H2 2013:Industry Analysis Report

  1. 1. Pulmonary Fibrosis - Pipeline Review, H2 2013 Global Markets Directs, 'Pulmonary Fibrosis Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. table Of Contents table Of Contents 2 list Of Tables 6 list Of Figures 6 introduction 7 global Markets Direct Report Coverage 7 pulmonary Fibrosis Overview 8 therapeutics Development 9 an Overview Of Pipeline Products For Pulmonary Fibrosis 9 pulmonary Fibrosis Therapeutics Under Development By Companies 11 Pulmonary Fibrosis - Pipeline Review, H2 2013
  2. 2. pulmonary Fibrosis Therapeutics Under Investigation By Universities/institutes 13 early Clinical Stage Products 14 comparative Analysis 14 discovery And Pre-clinical Stage Products 15 comparative Analysis 15 pulmonary Fibrosis Therapeutics - Products Under Development By Companies 16 pulmonary Fibrosis Therapeutics - Products Under Investigation By Universities/institutes 17 companies Involved In Pulmonary Fibrosis Therapeutics Development 18 eli Lilly And Company 18 lpath, Inc. 19 mesoblast Ltd 20 nicox Sa 21 oncothyreon Inc 22 pharmaxis Ltd. 23 paloma Pharmaceuticals, Inc. 24 digna Biotech, S.l. 25 aquinox Pharmaceuticals Inc. 26 angion Biomedica Corp. 27 centocor Ortho Biotech, Inc. 28 fibrotech Therapeutics Pty. Ltd. 29 fcb-pharmicell Co.,ltd. 30 clarassance, Inc. 31 pulmonary Fibrosis - Therapeutics Assessment 32 assessment By Monotherapy Products 32 assessment By Route Of Administration 33 assessment By Molecule Type 35 drug Profiles 37 lpathomab - Drug Profile 37 product Description 37 mechanism Of Action 37 r&d Progress 37 p-17 - Drug Profile 38 product Description 38 mechanism Of Action 38 r&d Progress 38 azx-100 - Drug Profile 39 product Description 39 mechanism Of Action 39 r&d Progress 39 px-866 - Drug Profile 42 product Description 42 mechanism Of Action 42 r&d Progress 42 Pulmonary Fibrosis - Pipeline Review, H2 2013
  3. 3. stnm-04 - Drug Profile 45 product Description 45 mechanism Of Action 45 r&d Progress 45 p-529 - Drug Profile 46 product Description 46 mechanism Of Action 46 r&d Progress 46 aqx-1125 - Drug Profile 48 product Description 48 mechanism Of Action 48 r&d Progress 48 btx-201 - Drug Profile 49 product Description 49 mechanism Of Action 49 r&d Progress 49 gr-md-02 - Drug Profile 50 product Description 50 mechanism Of Action 50 r&d Progress 50 drug For Osteoarthritis And Pulmonary Fibrosis - Drug Profile 52 product Description 52 mechanism Of Action 52 r&d Progress 52 icg-001 - Drug Profile 53 product Description 53 mechanism Of Action 53 r&d Progress 53 cg-1011 - Drug Profile 54 product Description 54 mechanism Of Action 54 r&d Progress 54 ang-3298 - Drug Profile 55 product Description 55 mechanism Of Action 55 r&d Progress 55 c-201 - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 galectin-3 Inhibitors - Drug Profile 57 product Description 57 mechanism Of Action 57 Pulmonary Fibrosis - Pipeline Review, H2 2013
  4. 4. r&d Progress 57 sdp-051 - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 ft-011 - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 ct-140 - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 pde-4a4 Inhibitors - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 ncx-466 - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 mc-1575 - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 lungcellgram - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 cpg Oligonucleotides - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 allogeneic Mesenchymal Precursor Cells For Asthma And Pulmonary Fibrosis - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 ly-2109761 - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 pxs-5033-a - Drug Profile 68 product Description 68 Pulmonary Fibrosis - Pipeline Review, H2 2013
  5. 5. mechanism Of Action 68 r&d Progress 68 transforming Growth Factor Beta Receptor Antagonists - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 drug Inhibiting Igf-1r - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 pulmonary Fibrosis Therapeutics - Drug Profile Updates 72 pulmonary Fibrosis Therapeutics - Discontinued Products 84 pulmonary Fibrosis Therapeutics - Dormant Products 85 pulmonary Fibrosis - Product Development Milestones 86 featured News & Press Releases 86 jul 11, 2013: Prometic's Lead Drug Candidate, Pbi-4050, On Track To Enter Clinical Trial Program In September 2013 86 jun 05, 2013: Genoa Pharma And Mcmaster University Demonstrate In Vivo Benefit Of Inhaled Pirfenidone Offering Greater Pulmonary Fibrosis Efficacy Than Oral Therapy 86 may 08, 2012: Boehringer Ingelheim To Present Additional Data From Phase Ii Study Of Bibf 1120 At Ats 2012 87 jul 06, 2011: Capstone Reports Positive Pre-clinical Results Of Azx100 In Pulmonary Fibrosis 87 mar 05, 2010: Immuneregen Forms Partnership With Bachem For Manufacturing Of Homspera 88 may 18, 2009: Oncothyreon's Px-866 Is Effective In Preclinical Model Of Pulmonary Fibrosis 89 mar 17, 2009: Compugen Announces Positive Therapeutic Effects Of Relaxin Receptor Peptide Ligand Cgen-25009 In Pulmonary Fibrosis Animal Model 89 appendix 91 methodology 91 coverage 91 secondary Research 91 primary Research 91 expert Panel Validation 91 contact Us 92 disclaimer 92 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Pulmonary Fibrosis - Pipeline Review, H2 2013
  6. 6. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Pulmonary Fibrosis - Pipeline Review, H2 2013